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The pathogenesis of systemic lupus erythematosus (SLE) can be divided into discrete stages. Both environmental
and genetic factors contribute to the development of the disease. Triggers such as hormones, microbes, diet, and
drugs can elicit autoimmunity. These elements and epigenetic changes drive a sustained loss of tolerance and the
spread of autoimmunity. Subsequently, immune-complex deposition and autoantibody-mediated tissue damage
can cause chronic inflammation and irreversible damage in end organs. Active SLE is characterized by a remark-
ably homogeneous gene expression pattern with overexpression of interferon (IFN)-induced genes, which is the
so-called IFN signature. The type I IFN system has been suggested as a driving force behind the disease, that is,
nucleic acids derived from apoptotic cells and neutrophil extracellular traps provide the critical ligands to drive
expression of type I IFNs from plasmacytoid dendritic cells via toll-like receptors. Type I IFNs increase the pro-
duction of B cell-activating factor (BAFF) by macrophages and dendritic cells. BAFF is a cell survival and matu-
ration factor for B cells. Type I IFNs also decrease regulatory T cell function. Both T cells and B cells participate
in autoreactivity, with B cells ultimately producing autoantibodies. Interleukin 17 production by T cell also con-
tributes to organ infiltration by neutrophils.
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cell activating factor belonging to the tumor necro-







Figure　1　Immunopathogenesis of systemic lupus erythematosus (SLE).
In patients with SLE, nucleic acids derived from apoptotic cells and neutrophil extracel-
lular traps (NETs) provide the critical ligands to drive the expression of type I interferons 
(IFNs) from plasmacytoid dendritic cells (pDCs) via toll-like receptors. The produced type I 
IFN stimulates both innate and adaptive immune systems, contributing to loss of tolerance 
and a sustained autoimmune disease process. Type I IFNs promote the differentiation of 
monocytes into conventional dendritic cells (cDCs) and the expression of MHC class II mol-
ecules and the costimulatory molecules CD80 and CD86 by these dendritic cells (DCs). Na-
ïve T cells interact with cDCs and differentiate into T follicular helper (Tfh) cells. Tfh cells 
promote B cell maturation in germinal centers through the production of interleukin 21 
(IL-21). Type I IFNs also increase the production of B cell-activating factor (BAFF) by mac-
rophages and DCs. BAFF is a cell survival and maturation factor for B cells. Plasma cells 
ultimately produce autoantibodies. Immune-complex deposition and autoantibody-mediated 


































Table　1　Autoantibodies in systemic lupus erythematosus.
Autoantibody Clinical presentation Prevalence (%)
Antinuclear antibody/anti-cytoplasmic antibody
Anti-dsDNA antibody* nephritis 60-80
Anti-histone antibody 60-70
Anti-Sm antibody* neuropsychiatric syndrome, nephritis 20-30
Anti-Ro/SS-A antibody neonatal lupus, subacute cutaneous lu-
pus erythematosus
30-40
Anti-La/SS-B antibody sicca syndrome 5-15
Anti-U1-RNP antibody Raynaud’s phenomenon, pulmonary hy-
pertension
30-50
Anti-PCNA antibody thrombocytopenia, nephritis 3-5
Anti-ribosomal P antibody neuropsychiatric syndrome, liver injury 10
LE cell* (Anti-DNA-histone complex antibody) 10
Anti-blood cell antibody
Anti-lymphocyte antibody lymphocytopenia 5-20
Anti-neutrophil antibody granulocytopenia










Anti-thyroglobulin antibody Hashimoto’s thyroiditis
*SLE disease specific antibody.
CD3ζ鎖が欠如し２２），FcRγ鎖で代替されているこ
と２３），それが通常の T細胞では見られない過剰に発

















































































































の neutrophils extracellular traps（NETs）由 来 の



















I型 IFN誘導活性があり，cyclic guanosine mono-
phosphate（GMP）-AMP synthase（cGAS）や stimu-
―56―
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